BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25511622)

  • 1. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
    Pui CH
    Front Med; 2015 Mar; 9(1):1-9. PubMed ID: 25511622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia.
    Wu C; Li W
    Crit Rev Oncol Hematol; 2018 Jun; 126():100-111. PubMed ID: 29759551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognosis prediction for childhood acute lymphoblastic leukemia--review].
    Liu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):202-6. PubMed ID: 17490555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in childhood acute lymphoblastic leukemia.
    Pui CH
    J Formos Med Assoc; 2004 Feb; 103(2):85-95. PubMed ID: 15083238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Childhood and adolescent lymphoid and myeloid leukemia.
    Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
    Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia.
    Kager L
    J BUON; 2009 Sep; 14 Suppl 1():S181-6. PubMed ID: 19785064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Gutierrez-Camino A; Bilbao-Aldaiturriaga N; Pombar-Gomez M; Martin-Guerrero I; Garcia-Orad A
    Pharmacogenomics; 2014 Jul; 15(10):1383-98. PubMed ID: 25155938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
    Dulucq S; Laverdière C; Sinnett D; Krajinovic M
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):699-719. PubMed ID: 24673379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular diagnostics in the treatment of childhood acute lymphoblastic leukemia.
    Rubnitz JE
    J Biol Regul Homeost Agents; 2000; 14(3):182-6. PubMed ID: 11037050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Childhood acute lymphoblastic leukemia: update on prognostic factors.
    Vrooman LM; Silverman LB
    Curr Opin Pediatr; 2009 Feb; 21(1):1-8. PubMed ID: 19242236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric acute lymphoblastic leukemia.
    Carroll WL; Bhojwani D; Min DJ; Raetz E; Relling M; Davies S; Downing JR; Willman CL; Reed JC
    Hematology Am Soc Hematol Educ Program; 2003; ():102-31. PubMed ID: 14633779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of childhood acute lymphoblastic leukemia.
    Brenner TL; Pui CH; Evan WE
    Curr Opin Mol Ther; 2001 Dec; 3(6):567-78. PubMed ID: 11804271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of drug resistance in acute lymphoblastic leukemia].
    Inukai T
    Rinsho Ketsueki; 2016; 57(10):2022-2028. PubMed ID: 27795510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific genetic lesions and their influence on therapy in pediatric acute lymphoblastic leukemia.
    Downing JR; Mullighan CG
    Hematology Am Soc Hematol Educ Program; 2006; ():118-22, 508. PubMed ID: 17124049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
    Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
    Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic studies in acute lymphoblastic leukemia.
    Pui CH
    Acta Paediatr Taiwan; 2000; 41(6):303-7. PubMed ID: 11198935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.
    Ansari M; Krajinovic M
    Curr Opin Pediatr; 2007 Feb; 19(1):15-22. PubMed ID: 17224657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
    Bhatla T; Jones CL; Meyer JA; Vitanza NA; Raetz EA; Carroll WL
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):413-8. PubMed ID: 24942023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.